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Summary. In any chronic liver disease (CLDs),
whatever the aetiology, reiteration of liver injury results
in persisting inflammation and progressive fibrogenesis,
with chronic activation of the wound healing response in
CLDs, representing a major driving force for progressive
accumulation of ECM components, eventually leading to
liver cirrhosis. Cirrhosis is characterized by fibrous septa
dividing the hepatic parenchyma into regenerative
pseudo-lobules, as well as by extensive changes in
vascular architecture, the development of portal
hypertension and related complications. Liver
fibrogenesis (i.e., the dynamic process leading to
increased deposition of ECM and much more) can lead
to different patterns of fibrosis and is sustained by
myofibroblast-like cells (MFs) of different origin, with
activated hepatic stellate cells (HSC/MFs) being the
major cell type involved. Major pro-fibrogenic
mechanisms also include oxidative stress, as well as
derangement of epithelial-mesenchymal interactions
and, as recently suggested, the process of epithelial to
mesenchymal transition (EMT). 
Liver fibrosis has been considered traditionally as an
irreversible process but experimental and clinical
literature data published in the last decade have
suggested that both the removal of the aetiological agent
or condition, as well as an effective therapy, can result in
significant regression of liver fibrosis. This is usually
associated, particularly in animal models, with induction
of apoptosis in MFs but, unfortunately, human HSC/MFs
are much more resistant to apoptosis than murine MFs.
However, clinical studies provided no unequivocal
evidence for a complete reversal of cirrhosis or a
significant reversal of vascular changes in conditions of
established cirrhosis.
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Progressive liver fibrogenesis: the process leading
to excess deposition of extracellular matrix and
eventually to liver cirrhosis
Introductory remarks
Chronic liver diseases (CLDs) are typically
characterized by reiteration of hepatocyte injury due to
either chronic viral infection by hepatotropic viruses
(mainly hepatitis B and C viruses) or to autoimmune
injury, as well as to metabolic and toxic/drug – induced
causes, with chronic alcohol consumption being
predominant in western countries (Fig. 1). This results in
a chronic activation of the wound healing response that,
together with other mechanisms like oxidative stress,
derangement of epithelial-mesenchymal interactions and
epithelial to mesenchymal transition, sustains persistent
liver fibrogenesis (i.e., the process) and represents a
major driving force for liver fibrosis (i.e., the result)
(Parola and Robino, 2001; Friedman, 2003, 2004;
Bataller and Brenner, 2005; Friedman 2008b; Novo and
Parola, 2008; Parola et al., 2008). 
Liver fibrogenesis can be envisaged as a dynamic
and highly integrated molecular, tissue and cellular
process that leads to the progressive accumulation of
extracellular matrix (ECM) components in an attempt to
limit hepatic damage in a CLD irrespective of the
aetiology. This eventually leads to liver cirrhosis and
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hepatic failure, with cirrhosis (Fig. 2) being currently
defined as an advanced stage of fibrosis, characterized
by the formation of regenerative nodules of parenchyma
surrounded and separated by fibrotic septa, and
associated with significant changes in organ vascular
architecture, development of portal hypertension and
related complications (variceal bleeding, hepatic
encephalopathy, ascites and hepatorenal syndrome)
(Friedman, 2003, 2004, 2008b; Pinzani and Rombouts,
2004; Bataller and Brenner, 2005). 
The clinical relevance of fibrogenic progression in CLDs
Progressive liver fibrogenesis has a tremendous
clinical impact which is best described by the following
scenario: 
a) on the basis of current reports, it can be estimated
that millions of patients worldwide are affected by a
form of CLD, with HCV chronic infection becoming
predominant in western countries, followed by and/or
associated with chronic alcohol consumption, and HBV
and HCV chronic infections being predominant in Asia
and Africa; 
b) 25-30% of patients affected by CLDs are
expected to develop significant fibrosis and cirrhosis; 
c) liver cirrhosis is currently the most common non-
neoplastic cause of death in Europe and USA and overall
represents the 7th most common cause of death in
western countries; 
d) mortality rate is further increased by primary liver
cancer (i.e., hepatocellular carcinoma or HCC) which is
strictly associated with liver cirrhosis; 
e) a peak for advanced CLD (mainly associated with
HCV chronic infection) has been predicted for Europe in
the next decade which is likely to face a significant
reduction of organ donation for liver transplants, which
at present represent the only effective treatment option;
f) a number of clinical features have been identified
that may serve as major predictors for the development
of significant fibrosis and cirrhosis:
- male gender (age <50 years);
- age at infection (particularly for HCV);
- daily alcohol intake; 
- hepatic iron content;
- obesity and diabetes mellitus;
- individual factors, including mainly differences in
immune responses vs infectious agents and related auto-
antigens as well as individual differences in drug
metabolism. 
In fact, fibrotic progression towards cirrhosis has
been estimated to last for at least 10 – 15 years;
however, progression towards cirrhosis may be
extremely rapid and completed within 2-3 years in
children affected by biliary atresia or familiar
progressive intrahepatic cholestasis, as well as in a
subset of patients following OLT for HBV- or HCV –
related cirrhosis (Poynard et al., 1997; Pinzani et al.,
2001; Parola et al., 2008).
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Fig. 1. Events involved in
fibrosclerotic development of
CLDs. CLDs may involve
different aetiological agents or
condit ions able to cause
persisting parenchymal liver
injury (1) and then hepatocyte
(HC) necrotic or apoptotic cell
death (2). As a result, a
persistent inflammatory
reaction can occur (3), which
may significantly affect the
progression of the disease by
either contributing to the
perpetuation of injury (4) or by
'creating' a growth factor,
cytokine and mediator pattern
favoring tissue repair and the
activation of ECM-producing
cells (5). This chronic
scenario, with time will lead to
activation of myofibroblast-like
cells that, in turn, wil l
contribute either to
perpetuation of inflammation
by releasing pro-inflammatory
mediators (7) or to the wound
healing response by excess
and progressive accumulation
of fibrillar ECM components. If
the aetiological agent or causal condition persists, the CLD can undergo a fibrosclerotic progression to cirrhosis and liver failure.
The different patterns of fibrosis
Fibrotic progression of CLDs has been described to
proceed through at least four distinct patterns of fibrosis
that seem strictly related to the underlying cause of
CLD. The main fibrotic patterns (as detailed in the next
paragraphs), are also related to the “topographic site” of
tissue injury, to the involvement of different populations
of MFs and the predominant pro-fibrogenic mechanism
(Cassiman and Roskams, 2002; Pinzani and Rombouts,
2004; Parola et al., 2008). 
Bridging fibrosis
This is a pattern of ECM deposition and septa
formation that is typically described mainly in the liver
of patients carrying HBV- or HCV-related chronic
hepatitis. In this pattern one can appreciate, as a result of
portal-central bridging necrosis, the development of
fibrotic septa that apparently connect portal areas with
the area of central vein (i.e, portal-central septa) or
different portal areas (portal-portal septa), as well as of
blind septa in the parenchyma. Within this pattern are
included the classic images of fibrotic septa leading to
the obliteration of central veins and of early changes in
vascular architecture and connections with the portal
system, which eventually favor the development of
portal hypertension. It is believed that chronic activation
of wound healing is likely to represent the major
pathogenic mechanism driving this pattern of fibrosis
progression; moreover, hepatic pro-fibrogenic MFs in
these settings can be either derived from HSCs, portal
fibroblasts, or even from bone marrow stem cells (see
later). However, oxidative stress and reactive oxygen
species (ROS) have also been described to offer a
significant pathogenic contribution. 
Perisinusoidal/pericellular fibrosis
This is a pattern that has been described in CLDs
due to excess alcoholic consumption (ASH or alcoholic
steatohepatitis) or to metabolic derangement and then
progressing from non-alcoholic fatty liver disease
(NAFLD) to non-alcoholic steatohepatitis (NASH). In
these clinical settings excess deposition of ECM
components is seen first in the space of Disse and leads
to the peculiar “chicken-wire” pattern. MFs derived from
activation of hepatic stellate cells (HSC/MFs) and ROS
and oxidative stress have a predominant pro-fibrogenic
and pathogenic role, respectively.
Biliary fibrosis
This definition is used in those conditions affecting
the biliary tree that are characterized by the rather
peculiar scenario of concomitant proliferation of reactive
bile ductules and periductular MFs (here mainly derived
from periportal fibroblasts or, see later, by EMT
transition of cholangiocytes). This scenario is dominated
by the consequent formation of portal-portal septa that
for a long time do not significantly affect vascular
connections with the portal system. For this pattern,
either significant alterations in the interactions between
cholangiocytes and mesenchymal cells or cholangiocyte
transition into MF-like phenotype, as well as oxidative
stress, have been proposed as major mechanisms.
Centrilobular fibrosis
This is a pattern that has to be included in this
classification but is really independent of CLDs
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Fig. 2. Immunohistochemical analysis performed on paraffin liver
sections from patients with hepatitis C virus (HCV) related liver cirrhosis
(METAVIR F4). Sections (2 µm thick) were incubated with specific
antibodies raised against α-SMA that positively stain myofibroblast – like
cells. Primary antibodies were labeled by using EnVision, HRP-labelled
System (DAKO) antibodies and visualized by 3’-diaminobenzidine
substrate.
progression. Indeed, centrilobular fibrosis is typically
described in patients affected by chronic heart failure in
which a significant alteration of venous outflow is
realized. In these patients fibrotic septa develop between
central vein areas (central-central septa) and lead to the
unique scenario often defined as “reversed lobulation”.
Hepatic myofibroblasts.
Hepatic myofibroblasts (MFs) is a collective
definition for a heterogenous population of pro-
fibrogenic cells, mostly positive for α-smooth muscle
actin (αSMA), which can be easily identified in
chronically injured livers (i.e., fibrotic or cirrhotic) in
either clinical or experimental conditions (Cassiman et
al., 2002; Parola et al., 2008; Novo et al., 2009). On the
basis of their antigen profile and/or tissue localization,
different populations of MFs have been described: a)
portal/septal MFs (PS/MFs), which express an
overlapping antigen repertoire and are commonly found
in the expanded connective tissue around portal tracts
(portal MFs) as well as in the inner part of fibrotic septa
(septal MFs); b) interface MFs (IF/MFs), which are
primarily found where active fibrogenesis occurs, which
is at the edge between fibrotic septa and the surrounding
parenchyma; c) activated, myofibroblast-like, hepatic
stellate cells (HSC-MFs), αSMA-positive cells found
primarily in or around capillarised sinusoids of
fibrotic/cirrhotic livers. 
In the last decade, literature data have revealed that
pro-fibrogenic hepatic MFs can originate from different
cellular sources (Fig. 3), with a relative contribution that
may vary depending on the aetiology of the chronic liver
disease (CLD) and/or the prevailing fibrogenic
mechanism (Friedman, 2008b; Parola et al., 2008). The
following cell sources or mechanisms have been
described:
Hepatic stellate cells
Hepatic stellate cells are perisinusoidal cells of still
uncertain embryological origin, responsible for the
synthesis of basal membrane like – ECM components of
the sub-endothelial space of Disse and for storage and
metabolism of vitamin A and retinoids. HSC have been
also proposed to act as “liver specific pericytes” and to
significantly contribute to hepatic development and
regeneration (Friedman, 2008a). HSC are still
considered as the most relevant cell source for pro-
fibrogenic MF-like cells for which the process of
activation and pro-fibrogenic mechanisms are best
characterized (Friedman, 2008a). HSC-MFs are involved
in most, if not all, clinical conditions of CLDs, with an
involvement which is prevalent in the pattern of
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Fig. 3. Hepatic MFs have
been proposed to originate
following a common process
of activation/trans-
differentiation from hepatic
stellate cells and portal
fibroblasts, or by recruitment
and differentiation of bone
marrow-derived cells like
mesenchymal stem cells
(MSC) or circulating
fibrocytes, as well as by a
process of epithelial to
mesenchymal transition
involving hepatocytes or
cholangiocytes. In the figure
are also indicated the
established or suggested role
for human MFs.
“perisinusoidal/pericellular fibrosis” that is typically
found in the early stages of both NASH and ASH.
Moreover, HSC may significantly also contribute to the
origin of interface MFs and then to the pattern of
“bridging fibrosis” which predominates in the
fibrotic/cirrhotic liver of HCV chronic patients (Parola et
al., 2008). 
Where the process of activation of HSC to HSC/MFs
is concerned, this process has been investigated by
following changes in morphology and phenotypical
responses observed in HSC, obtained from either human
or rat liver, when cultured on plastic substrate. HSC in
these conditions undergo a trans-differentiation from the
original “storing phenotype” to the one of activated
MFs, classically including the following relevant
features (Friedman, 2000, 2003, 2004; Pinzani and
Marra, 2001; Pinzani and Rombouts, 2004; Bataller and
Brenner, 2005): 
- high proliferative attitude; 
- increased synthesis of ECM components, particularly
fibrillar collagens, as well as of factors involved in ECM
remodelling; 
- ability to migrate (chemotactic response); 
- increased synthesis of growth factors (autocrine loops)
and pro-inflammatory cytokines; 
- contractility in response to vaso-active compounds;
- resistance to apoptosis induction (see later). 
Although the scenario proposed on the basis of “in
vitro” studies may represent an over-simplification, it is
still considered as reasonably similar to the one that is
likely to occur “in vivo”. It is likely that at least portal
fibroblasts as well as bone marrow – derived cells may
undergo a similar process of activation in conditions of
CLD. 
Portal fibroblasts
These cells are located in the connective tissue of
portal areas and their activation into MFs is believed to
be relevant in ischemic conditions, as well as in
obstructive cholestatic diseases (pattern of “biliary
fibrosis”, Parola et al., 2008). Because of overlapping
antigen repertoire, portal fibroblasts are considered to
give origin also to septal MFs. 
Bone marrow-derived cells
Recent studies have provided evidence indicating
that under conditions of chronic liver injury, pro-
fibrogenic MFs (mainly IF/MFs and some portal MFs)
can originate from progressive recruitment of bone
marrow derived cells (Forbes et al., 2004). At least two
different populations of bone marrow have been shown
to engraft chronically injured livers and differentiate into
α-SMA positive MFs, including mesenchymal stem cells
or MSC (Russo et al., 2006; Valfrè di Bonzo et al., 2008;
Li et al., 2009) and circulating fibrocytes (Kisseleva et
al., 2006). The effective contribution of MSCs has been
found to vary depending on the source (human or
murine), as well as the experimental protocol for cell
transplant, with a recent report even suggesting that
collagen deposition by bone marrow-derived cells may
be negligible (Higashiyama et al., 2009), although the
conclusions of the latter study are at present a matter of
debate (Kallis and Forbes, 2009). 
Cholangiocytes and hepatocytes
Recent reports have suggested that pro-fibrogenic
cells may also originate from either cholangiocytes or
hepatocytes through a process of epithelial to
mesenchymal transition. Such a process has been
described originally in embryologic and fetal
development, and then involved in cancer cell
invasiveness and progression, as well as in organ
fibrogenesis. Concerning liver fibrogenesis, only two
reports have suggested that α-SMA negative but FSP-1
(fibroblast specific protein type 1) positive MFs may
originate from hepatocytes that underwent full EMT
program (Zeisberg et al., 2007) and that fibrogenesis
may be prevented by treatment with BMP-7 (bone
morphogenic protein – 7), a molecule that has been
reported to significantly affect EMT process (Dooley et
al., 2008). More data have been published that suggest a
putative contribution by EMT of cholangiocytes in
human and experimental conditions of biliary fibrosis
and these studies will be recalled in the following
section dedicated to the pro-fibrogenic mechanisms. At
present, the real contribution of EMT to the fibrogenic
progression of CLDs is a matter of intense debate. 
Major pro-fibrogenic mechanisms in liver fibrogenesis 
A limited number of mechanisms have been
proposed to sustain liver fibrogenesis, including chronic
activation of the wound healing response, oxidative
stress and altered modulation of epithelial-mesenchymal
interactions, as well as the already cited mechanism of
EMT (Pinzani and Marra, 2001; Pinzani and Rombouts,
2004; Bataller and Brenner, 2005; Elsharkawy et al.,
2005; Iredale, 2007; Kallis et al., 2007; Friedman,
2008a,b; Novo and Parola, 2008; Parola et al., 2008). 
Chronic activation of the wound healing reaction 
This is believed to represent the most common and
relevant mechanism in hepatic fibrogenesis. The
hallmarks of the involvement of chronic activation of the
wound healing reaction are the following (Parola et al.,
2008):
- the persistence of hepatocellular and cholangiocellular
damage with variable degree of necrosis and apoptosis;
- the presence of an inflammatory infiltrate composed of
mononuclear cells and lymphocytes;
- the involvement of different pro-fibrogenic and ECM –
producing cells that, as just mentioned, are also
characterized by intense proliferative attitude, migration
and contractility;
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- quantitative (excess deposition) and qualitative
alteration in the composition of the ECM, being
associated with a limited ability to remodel and remove
the typical fibrillar-like collagens and a persistent
attempt at liver regeneration. 
Chronic activation of wound healing reaction, as
well as of hepatic myofibroblasts is, in turn, sustained by
several growth factors and cytokines. Several
experimental and clinical studies have dissected those
intracellular signalling pathways relevant for the pro-
fibrogenic effect of these soluble factors and their
receptors, as a basis for future development of selective
therapeutic strategies. These factors include platelet-
derived growth factor (PDGF), transforming growth
factor (TGF)ß, connective tissue growth factor (CTGF),
endothelin-1 (ET-1), monocyte chemotactic protein
(MCP)-1, and tumour necrosis factor (TNF), to name
just a few (Bataller and Brenner, 2005; Friedman
2008a,b; Parola et al., 2008). More recently, the list of
polypeptide mediators has been implemented by the
addition of other soluble factors, including adipokines
and pro-angiogenic cytokines. 
Where adipokines are concerned, they have been
proposed as pro-fibrogenic mediators in conditions of
non alcoholic fatty liver disease (NAFLD) and non
alcoholic steatohepatitis (NASH). Adipokines are
cytokines exclusively or predominantly secreted by the
adipocytes and the best known representative adipokine,
leptin, has been found to be increased in obese patients
with NASH as well as in other patients with a CLD of
different aetiology. 
Studies linking leptin to fibrogenesis range from
experimental animal models (Ikejima et al., 2001) to “in
vitro” studies showing that leptin can indeed exert a
number of biological actions on HSC, including up-
regulation of collagen, stimulation of cell proliferation,
prevention of apoptosis and up-regulation of pro-
inflammatory and pro-angiogenic cytokines (Aleffi et
al., 2005; Marra and Bertolani, 2009). This scenario is
likely to be counteracted by adiponectin, another
adipokine which is known to be decreased in obese
and/or diabetic (Type II) patients. Adiponectin has been
shown to ameliorate metabolic derangements and liver
damage in mouse models of NASH (Xu at al., 2003), to
exert a direct antifibrogenic role and to induce HSC
apoptosis (Ding at al., 2005). 
Concerning angiogenesis and pro-angiogenic
cytokines, formation of new vessels is known to occur in
several organs and to be critical for both growth and
repair of tissues in several pathophysiological conditions
(Carmeliet, 2003). As will be emphasized in a following
section, the current feeling is that angiogenesis, as
triggered by conditions of hypoxia and by directly
involving hepatic MFs, can proceed in association with
and favour progressive liver fibrogenesis. 
Oxidative stress
Involvement of oxidative stress, reactive oxygen
species (ROS) and other reactive intermediates has been
unequivocally documented in all human major clinical
conditions of CLDs, as well as in most experimental
models of liver fibrogenesis, with a predominant role in
sustaining fibrogenesis in NASH and ASH patients. An
extensive analysis of the role of oxidative stress in liver
fibrogenesis is out of the scope of the present paper and
the interested reader can find more details in specialized
reviews (Parola and Robino, 2001; Novo and Parola,
2008). Here only major concepts will be briefly recalled. 
1. Oxidative stress in CLDs results from either
increased generation of ROS and other reactive
intermediates, as well as by decreased efficiency of
antioxidant defences, a typical feature of CLDs. It
should be noted that oxidative stress in CLDs can be
either responsible for potentially toxic consequences or
actively contributes to excessive tissue remodelling and
fibrogenesis. ROS and other reactive mediators such as
the aldehydic end-product of lipid peroxidation 4-
hydroxy-2,3-nonenal (HNE) can be released either by
activated inflammatory cells or from hepatocytes
directly or indirectly damaged by the specific
aetiological agent or conditions. As a relevant example,
generation of ROS within hepatocytes may represent a
consequence of an altered metabolic state (like in
NAFLD and NASH) or of ethanol metabolism (ASH),
with ROS being then mainly generated by mitochondrial
electron transport chain or through the involvement of
selected cytochrome P450 isoforms like CYP2E1
(Angulo, 2002; Albano, 2006; Tilg and Hotamisligil,
2006; Zamara et al., 2006). Severe oxidative stress,
presumably by favouring mitochondrial permeability
transition as well as by affecting the integrity of
biological membranes, cytoskeleton as well as
transcription and protein synthesis, is indeed able to
promote hepatocyte death (necrotic and/or apoptotic). 
2. ROS, HNE and other oxidative stress – related
mediators released by damaged hepatocytes or activated
inflammatory cells can directly affect the behaviour of
human HSC/MFs and likely of other MF-like cells (Fig.
4). As a matter of fact, ROS and HNE have been
reported to up-regulate expression of critical pro-
fibrogenic genes, including procollagen type I, TIMP-1
and the pro-inflammatory chemokine MCP-1, possibly
through activation of a number of critical signal
transduction pathways and transcription factors,
including activation of JNKs, AP-1 and, only for ROS,
NF-κB (Parola et al., 1998; Parola and Robino, 2001;
Zamara et al., 2004; Friedman, 2004; Bataller and
Brenner, 2005; Novo et al., 2006a; Novo and Parola,
2008). 
ROS may also contribute to positively modulate
proliferation of rat HSC/MFs but this does not apply to
human MFs exposed to HNE, which rather is able to
inhibit basal and PDGF-stimulated DNA synthesis or
even induce cell death (Robino et al., 2000; Zamara et
al., 2004; Novo et al., 2006a). Low levels of
extracellularly generated superoxide anion, but not H2O2
or HNE, are able to stimulate migration of human
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HSC/MFs through activation of Ras/Erk signalling
(Novo et al., 2006a) and also of isoforms 1 and 2 of c-
Jun-NH2-kinases (JNK1/2) (Novo et al., 2009;
submitted). 
3. A redox sensitive role should also be recognized
to intracellular and NADPH-oxidase-dependent ROS
generation within human and rat HSC/MFs that has been
reported to occur in response to several known pro-
fibrogenic mediators, including PDGF-BB, angiotensin
II, and the adipokine leptin (De Minicis et al., 2006).
ROS generated within HSC/MFs can act as positive
modulators or pro-fibrogenic signalling pathways and,
indeed, selective inhibition of NADPH oxidase can
effectively reduce phenotypic responses of HSC/MFs
(reviewed by De Minicis et al., 2006). Moreover,
genetically manipulated mice lacking p47phox (i.e., a
crucial subunit of NADPH oxidase) have been shown to
be protected from development of experimental fibrosis
(Bataller et al., 2003). Intracellular and NADPH
oxidase-related generation of ROS has also been
reported to follow “in vivo” and “in vitro” phagocytosis
of apoptotic bodies from damaged hepatocytes by
HSC/MFs and to result in procollagen type I increased
expression (Zhan et al., 2006). 
4. Oxidative stress may contribute to CLDs
progression also by affecting immune response.
Experimental studies (alcohol fed rodents) and clinical
data (patients affected by ALD, chronic HCV infection
or NAFLD) indicate that oxidative stress is associated
with the development of circulating IgG antibodies
directed against epitopes derived from protein modified
by lipid peroxidation products or against oxidized
cardiolipin. Titre of these antibodies correlate with
disease severity and, as recently proposed for NAFLD
patients, may serve as a prognostic predictor of
progression of NAFLD to advanced fibrosis (Albano et
al., 2007 and reference therein). Along these lines, a T
cell mediated response towards lipid peroxidation
derived antigens has been described in patients with
advanced ALD (Stewart et al., 2004). Immune response
triggered by oxidative stress may then play a significant
role in the progression of ALD, in the worsening of
chronic hepatitis C by alcohol intake and, possibly, even
in the progression of NAFLD. 
Derangement of epithelial – mesenchymal
interactions in cholangiopathies and/or epithelial to
mesenchymal transition? 
Clinical conditions known as cholangiopathies, a
group of progressive disorders representing a major
cause of chronic cholestasis in adult and pediatric
patients, share a common scenario characterized by
cholestasis, necrotic or apoptotic loss of cholangiocytes,
cholangiocyte proliferation and portal/periportal
inflammation and fibrosis. In these settings the so called
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Fig. 4. ROS and related
mediators (HNE, 4-hydroxy-
2,3-nonenal) as generated by
injured hepatocytes (including
hepatocytes in ASH and
NASH), activated Kupffer cells
or sinusoidal endothelial cells
as well as by damaged
mitochondria can operate as
pro-fibrogenic stimuli directly
on activated, MF-like, HSC
(HSC/MFs): a 'stellate centric'
view. MFs react by up-
regulating the expression of
pro-collagen type 1, MCP-1,
TIMP-1, TGFß1 as well as by
migrating and/or proliferating.
See text for more details.
“ductular reaction” (i.e., proliferation of bile ductular
cells or cholangiocytes) has been reported to be relevant
and to behave as the “pace maker of portal fibrosis”
(Roskams and Desmet, 1998). Ductular reaction is
characterized by intense proliferation of cholangiocytes
that is associated with significant changes in the
surrounding mesenchymal cells, first portal fibroblasts in
the portal connective tissue and then HSC when the
reaction starts to invade the surrounding parenchyma, as
well as with significant changes in the ECM. It is still
unclear whether the first event is represented by
phenotypic changes in proliferating cholangiocytes or by
changes in ECM, that in turn can lead to cholangiocyte
proliferation. However, several studies of the pre-EMT
era have reported evidence for an intense cross-talk
between cholangiocytes and surrounding mesenchymal
cells, possibly resulting in the release of cytokines and
pro-inflammatory mediators that are likely to be
responsible for the overall scenario described for
cholangiopathies. In fact, cholangiocytes are considered
active “cellular actors” in pathological conditions for
their ability to secrete several chemokines (IL-6α TNFß,
IL-8, MCP-1) and pro-fibrogenic polypeptide mediators
(PDGF-BB, ET-1, CTGF, TGFß2). This putative pro-
fibrogenic scenario is also sustained by the fact that
almost the same chemokines and pro-fibrogenic
polypeptides can also be produced by infiltrating
immune, inflammatory or mesenchymal cells (reviewed
in Pinzani and Rombouts, 2004). 
The scenario just described (i.e., alteration of
epithelial-mesenchymal interactions) has received a
relevant contribution by studies of the last 3-4 years that
have proposed a major pro-fibrogenic role for
cholangiocyte which in chronic conditions of injury may
undergo EMT to transform themselves into pro-
fibrogenic MF-like cells. 
As a necessary premise, it should be noted that EMT
is a fundamental process, paradigmatic of the concept of
cell plasticity, which has been originally described in
embryonic development, where cell migration and tissue
remodeling play a primary role in regulating
morphogenesis in multi-cellular organisms. As for its
original definition, EMT was focused on the formation
of mesenchymal cells from epithelial cells in different
areas of embryos. This process is characterized by the
loss of epithelial cell polarization as a result of
disappearance of specialized junctional structures,
cytoskeleton reorganization and organelle redistribution
and gradual acquisition of typical EMT – related
mesenchymal features and behavior (Lee et al., 2006;
Thiery and Sleeman, 2006; Moustakas and Heldin, 2007;
Baum et al., 2008; Cannito et al., 2009). The EMT
process in embryo development has a natural
counterpart, since embryonic mesenchymal cells can
eventually undergo a reverse transition process, known
as mesenchymal to epithelial transition or MET (Chaffer
et al., 2007), leading them to regain a fully differentiated
epithelial phenotype.
In the last decade the EMT process (and then
possibly MET) has been identified in at least two other
well defined pathophysiological conditions, including
organ fibrosis and cancer progression and metastasis,
leading to the recent suggestion that EMTs may even be
classified into three corresponding different subtypes
(Acloque et al., 2009; Kalluri and Weinberg, 2009;
Zeisberg and Neilson, 2009), defined as: Type 1 EMT,
involved in embryonic development; Type 2 EMT,
associated to tissue damage, regeneration and organ
fibrosis; Type 3 EMT, involved in cancer progression
and metastasis. 
However, the EMT programs and related major
morphological and functional events that have been
detected in either physiological or patho-physiological
conditions, are stimulated and regulated by a common
set, although very complex, of inducing stimuli, signal
transduction pathways, transcription factors and post
transcriptional mechanisms. 
Coming back to cholangiopaties, an involvement of
EMT has been first proposed for the animal model of
biliary fibrosis induced by bile duct ligation in rats (Xia
et al., 2006), in which cholangiocytes were found to co-
express α-SMA and cytokeratin 19 (CK-19, a BDEC
and HPCs marker), an EMT scenario fully reproduced
by treating in vitro primary cultures of cholangiocytes
with TGFß1 and prevented, both in vivo and in vitro, by
pre-treatment with HGF. The same scenario in BDL was
confirmed by other studies (Omenetti et al., 2008a,
2008b) where a clear cause-effect relationship between
EMT of cholangiocytes, appearance of portal MFs and
biliary fibrosis, as well as the closely related major
involvement of Hedgehog signalling pathway was first
described. 
Most importantly, an identical scenario was also
described in specimens from human patients affected by
primary biliary cirrhosis (Jung et al., 2007; Robertson et
al., 2007; Omenetti, 2008b), primary sclerosing
cholangitis (Kirby et al., 2008) and biliary atresia (Diaz
et al., 2008), again with a major pathogenic role for
Hedgehog and TGFß1-Smad2/3 signaling. 
At present, two reports from different laboratories
(Jung et al., 2008; Rygiel et al., 2008) have also
provided the first evidence for EMT in cholangiocytes
and/or hepatic progenitor cells (HPCs) in biopsies from
patients affected by alcoholic liver disease, again with
Hedgehog and TGFß1-Smad2/3 signalling having a
major role. These latter two studies may suggest that,
although the predominant role of HSC/MFs still remains
as a dogma (particularly in the early phases and during
progressive fibrogenesis), in a rather advanced phase of
ALD this process may potentially contribute to increased
ECM deposition in alcoholic patients. 
The emerging major role of angiogenesis in CLDs 
Angiogenesis is currently defined as a dynamic,
hypoxia - stimulated and growth factor - dependent
process, eventually leading to the formation of new
vessels from pre-existing blood vessels. In the last
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decade experimental and clinical studies have described
the occurrence of hepatic angiogenesis in a number of
different patho-physiological conditions, including those
involving inflammatory, fibrotic and ischemic features.
In particular, literature evidence is now suggesting that
hepatic angiogenesis is strictly associated with, and may
even favour fibrogenic progression of chronic
inflammatory liver diseases of different aetiology.
Indeed, in the context of chronic activation of the wound
healing response, typical of fibrogenic conditions, an
excess of aberrant neo-angiogenesis can occur. Mainly
for anatomical reasons, including the existence of two
different types of micro-vascular structures in the liver
(i.e. large vessels lined by a continuous endothelium vs.
sinusoids lined by a fenestrated endothelium), the
formation of new vessels assumes very distinct features
in chronic liver diseases (CLDs) and, ultimately,
represent a key factor in determining disease progression
to cirrhosis.
This hypothesis relies first on the established
concept that angiogenesis is a major process involved in
wound healing, being integrated with the inflammatory
process (Carmeliet, 2003). Moreover, human cirrhotic
livers, irrespective of the aetiology, are characterized by
enhanced vascular remodelling. Where angiogenesis in
CLDs is concerned, one also has to remember that
formation of fibrotic septa, as well as capillarization of
sinusoids (due to deposition of fibrillar ECM in the
space of Disse) can result in an increased resistance to
blood flow and oxygen delivery. These are the premises
for the development of hypoxia, which is the main and
most obvious stimulus for angiogenesis in any organ or
tissue, with transcription of hypoxia - sensitive pro-
angiogenic genes being modulated usually through
hypoxia inducible factors (HIFs). 
In addition, one should emphasize the well known
relationships in CLDs between the inflammatory process
and angiogenesis, with inflammatory response gaining
the role of a dynamic state relevant fibrogenesis
progression (Friedman, 2004, 2008b). Indeed, several
mediators of the inflammatory response are known to
stimulate other surrounding cells to express VEGF and
other pro-angiogenic factors (Carmeliet, 2004).
Moreover, other cytokines and mediators, known to be
over-expressed during the condition of chronic
inflammatory liver injury have been suggested to sustain
angiogenesis, including HGF, NO and PDGF (Medina et
al., 2004). Moreover, one should consider that: a) neo-
vessels are likely to significantly contribute to
perpetuation of the inflammatory response by expressing
chemokines and adhesion molecules promoting
recruitment of inflammatory cells; b) angiogenesis, early
in the course of a CLD, may even contribute to the
transition from acute to chronic inflammation (Jackson
et al., 1997).
In this section, a brief analysis of major findings and
concepts supporting the emerging pathogenic role of
angiogenesis in CLDs is offered, with a specific
emphasis on the crucial role of hypoxic conditions and
hepatic stellate cells (HSCs), particularly when activated
to the myofibroblast-like pro-fibrogenic phenotype. The
interested reader can refer to recent more comprehensive
reviews for more details (Medina et al., 2004; Fernandez
et al., 2009; Valfrè di Bonzo et al., 2009). The following
major concepts and findings should be outlined.
1. Angiogenesis and up-regulation of VEGF
expression has been documented in different models of
acute and chronic liver injury, including fibrosis induced
by chronic CCl4 treatment, bile duct ligation,
administration of diethylnitrosamine and methionine and
choline deficient diet, which is able to induce NAFLD
and NASH (Ankoma Sey et al., 1998; Rosmorduc et al.,
1999; Corpechot et al. 2002; Yoshiji et al., 2003; Medina
et al., 2004; Kitade et al., 2006; Novo et al., 2007;
Tugues et al., 2007; Taura et al., 2008; Moon et al.,
2009). The same scenario was also documented in
specimens from human fibrotic/cirrhotic liver and
hepatocellular carcinoma (Medina et al., 2003-2005,
Novo et al., 2007; Fernandez et al., 2009). Human
conditions of CLDs include chronic infection by HBV
and HCV, as well as autoimmune diseases such as
primary biliary cirrhosis (PBC) and primary sclerosing
cholangitis (PSC). 
2. In both experimental and clinical conditions
angiogenesis and fibrogenesis develop in parallel, as
unequivocally indicated by morphological images
showing a very high number of endothelial cells and
microvascular structures in portal tracts and, more
generally, within established fibrotic septa. Moreover,
the strict relationships between hypoxia, angiogenesis
and VEGF expression, as well as fibrogenesis in liver
specimens from fibrotic/cirrhotic rodent and human
livers, have been documented by several studies
(Rosmorduc et al., 1999; Corpechot et al., 2002; Tugues
et al., 2007) and unequivocally confirmed by a recent
report in which liver conditional HIF-1α - deficient mice
were subjected to BDL (Moon et al., 2009): in these
mice a very significant decrease in collagen type I and
α-SMA transcripts and related protein levels, as well as
of transcripts for PDGF and plasminogen activator
inhibitor-1 (PAI-1) was detected as compared to wild
type mice in which the typical scenario of biliary type
fibrosis and cirrhosis was associated to early and
sustained up-regulation of HIF-1α.
3. VEGF expression, as detected in either
experimental and clinical conditions, is mostly limited to
hepatocytes and to HSC/MFs and, possibly, other
hepatic myofibroblasts (Medina et al., 2004; Fernandez
et al., 2009; Valfrè di Bonzo et al., 2009). In normal
liver, VEGF expression is mostly limited to a few
hepatocytes, showing nuclear positivity for HIF1α,
constituting the first row around the centrilobular vein
(Bozova and Elpek, 2007; Tugues et al., 2007).
4. Other polypeptides have been involved in hepatic
angiogenesis associated with the fibrogenic progression
process in CLDs, including, in particular, leptin. This
adipokine, which has been suggested to exert a pro-
fibrogenic effect by promoting the development from
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non alcoholic fatty liver disease (NAFLD) to non
alcoholic steatohepatitis (NASH), can up-regulate the
expression of VEGF and Ang-1 expression, as well as of
the pro-inflammatory chemokine monocyte chemo-
attractant protein 1 or MCP-1 (Aleffi et al., 2005). The
pro-angiogenic role of leptin has been confirmed by a
study performed on Zucker rats, animals that naturally
develop leptin receptor mutations (Kitade et al., 2006),
receiving the steatogenic choline-deficient and
aminoacid defined (CDAA) diet. To the list of pro-
angiogenic mediators that may have a role in vascular
remodelling in cirrhosis, one should now include also
Hedgehog (Hh) ligands that, released from HSC/MFs,
cholangiocytes and possibly hepatic progenitor cells,
may promote changes in sinusoidal endothelial cell gene
expression resulting in capillarization of sinusoids and in
the release of vasoactive factors such as nitric oxide
(Witek et al., 2009). 
5. Hepatic MFs, which are involved in fibrogenesis,
have also been reported to play a significant pro-
angiogenic role. This is particularly true for hepatic
stellate cells even in physiological angiogenesis because
of their role as liver specific pericytes, connected to their
strategic location in the space of Disse and intimate
contact with sinusoidal ECs (Friedman 2008a). As for
recent literature data, HSC/MFs should be considered as
a hypoxia-sensitive, cyto- and chemokine-modulated
cellular crossroad between necro-inflammation,
pathological angiogenesis and fibrogenesis on the basis
of the following studies that outlined the following
major concepts: 
- HSC and HSC/MFs react to conditions of hypoxia
and to leptin by up-regulating transcription and synthesis
of VEGF, Angiopoietin 1, as well as of their related
receptors VEGFR-2 and Tie2 (Ankoma-Sey et al., 2000;
Wang et al., 2004; Aleffi et al., 2005; Novo et al., 2007) 
- HSC/MFs respond to the action of VEGF and
Angiopoietin 1 in terms of proliferation (Ankoma Sey et
al., 1998; Yoshiji et al., 2003; Olaso et al., 2003),
increased deposition of ECM components (Corpechot et
al., 2002; Olaso et al., 2003; Yoshiji et al., 2003), and
increased migration and chemotaxis (Novo et al., 2007). 
This is a scenario that is likely to be relevant for the
in vivo progression of a CLD. In either human and rat
fibrotic/cirrhotic livers (Novo et al., 2007) α-SMA-
positive MFs able to express concomitantly VEGF, Ang-
1 or the related receptors VEGFR-2 and Tie-2, are found
at the leading edge of tiny and incomplete developing
septa, but not in larger bridging septa. This distribution
may reflect the existence of an early phase of CLD,
occurring in developing septa, in which fibrogenesis and
angiogenesis may be driven/modulated by HSC/MFs,
and of a later phase occurring in larger and more mature
fibrotic septa where the chronic wound healing is less
active and fibrogenic transformation more established.
In the late setting pro-angiogenic factors are expressed
only by endothelial cells, a scenario that is likely to
favour the stabilization of the newly formed vessels. 
6. Angiogenesis may represent a putative therapeutic
target in the treatment of CLDs. The bulk of available
experimental data indeed indicate that antiangiogenic
therapy is effective in preventing progressive
fibrogenesis, as shown by administering old anti-
angiogenic drugs (Wang et al., 2000), antibodies able to
neutralize either VEGFR-1 (Flt-1) and/or VEGFR-2
(Flk-1) (Ankoma Sey et al., 1998; Morales-Ruiz and
Jimenez 2005; Morales-Ruiz et al., 2005), adenovirus
expressing soluble Tie-2 (AdsTie-2, where Tie-2 is the
receptor for Ang-1) (Taura et al., 2008), the multi-
targeted tyrosine kinase receptor inhibitors Sunitinib
(Tugues et al., 2007) or Sorafenib (Mejias et al., 2009).
Moreover, most of these treatments were also able to
significantly inhibit the development of portal
hypertension, porto-systemic collateral vessels and
hyperdynamic splanchnic circulation (Morales-Ruiz and
Jimenez 2005; Morales-Ruiz et al., 2005 ; Tugues et al.,
2007; Mejias et al., 2009). All these data suggest that
anti-angiogenic drugs may then represent an attractive
alternative therapeutic tool to prevent or significantly
slow down fibrosis progression towards cirrhosis,
bearing also in mind that this may also affect the
development of portal hypertension, including its
complications, and of liver cancer. This putative new
therapeutic strategy is at present debated and requires
properly designed clinical trials. A note of caution is
based on a very recent negative report in which the use
of the anti-angiogenic drug Celingitide (a specific
inhibitor of integrin αvß3) in two different animal
models of fibrosis surprisingly resulted in an overall
worsening of liver fibrosis (Patsenker et al., 2009). 
Reversal of liver fibrosis
As the reader should have realized from previous
sections, liver fibrogenesis can be envisaged as a very
dynamic process of wound healing, and possibly much
more, which is in the end responsible for excess
deposition of ECM (i.e., liver fibrosis) and all the other
related morphological and functional changes found in a
chronically injured liver. For many years liver fibrosis
and cirrhosis have been considered as irreversible, with
ortothopic liver transplantion being the only therapeutic
resolutive option. Although the concept of fibrosis and
cirrhosis reversal was first introduced by Popper and
Underfriend almost forty years ago (Popper and
Undenfriend, 1970) and later on by Perez-Tamayo
(Perez-Tamayo, 1979), the “irreversibility” postulate has
been really challenged only recently by data obtained
first in animal models of fibrosis and then in human
studies. Most authors involved have identified the issues
of MF apoptosis and increased degradation of excess
ECM as the crucial ones, providing that the aetiological
agent or condition may be eliminated or efficiently
counteracted by means of selective therapy (Iredale,
2001; Elsharkawy et al., 2005; Henderson and Iredale,
2007; Muddu et al., 2007). This has opened the way to
the search for more selective therapeutic strategies
designed to target more specifically hepatic MFs or
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specific ligand-receptor interactions or pro-fibrogenic
signalling pathways, in order to switch on or at least
potentiate fibrosis reversal. In the next sections, major
findings and concepts of this relatively new scenario will
be summarized, with an attempt to focus attention on
those critical issues that have emerged in the last few
years. 
Experimental evidence of liver fibrosis reversion 
The first unequivocal evidence for reversal of liver
fibrosis was provided in 1998 by a study from Iredale
and co-workers (Iredale et al., 1998) performed in the rat
by administering CCl4 for 4 weeks, a procedure resulting
in significant liver fibrosis. In this study it was described
for the first time that cessation of administration of the
hepatotoxic and pro-oxidant compound was followed by
a reversion to virtually normal histology. A few years
later homologous evidence was provided by the same
group using the BDL rat model of secondary biliary
fibrosis (Issa et al., 2001). In this study biliodigestive
anastomosis was undertaken after 3 weeks of BDL in
order to relieve the condition and once again, this was
followed by an almost complete histological reversion at
the end of a 42 day period of recovery. This was also the
first study to report that fibrosis reversal was associated
with a fivefold decrease in activated HSC (more likely
of MFs, as we will say today), as determined by α-SMA
staining. TUNEL staining indicated that loss of activated
HSC (HSC/MFs) resulted from an increase in the rate of
apoptosis during the first two days post biliodigestive
anastomosis. This study (see also later) was
accompanied by evidence for induction of apoptosis in
cultured rat HSC/MFs by TGFß1 and the protein
synthesis inhibitor cycloheximide, but prevented by
IGF-1, then suggesting a more general concept: HSC
apoptosis plays a critical role in the recovery from
biliary fibrosis and survival and, apoptosis of HSC are
likely to be regulated by growth factors expressed during
fibrotic liver injury. 
Issa and coworkers went further to show that
reversion was obtained in CCl4 chronic model, even
when an advanced stage of micronodular cirrhosis was
obtained after 12 weeks of administration of the
hepatotoxin. After one year from cessation of CCl4
administration micronodular cirrhosis underwent
significant remodeling to a macronodular cirrhosis;
moreover, expression of collagen type 1 and TIMP1
messenger RNA (mRNA) decreased significantly and
active MMPs were shown in livers during remodeling of
fibrosis (Issa et al, 2004). This was paralleled by
significant loss of more recently formed fibrils and a
decrease in perisinusoidal fibrosis and a thinning of
fibrotic septa. Once again, resolution was characterized
by apoptosis of HSC/MFs, predominantly at the borders
of fibrotic septa. Residual septa, not remodeled after one
year, were characterized by trans-glutaminase-mediated
cross-linking and relative hypo-cellularity. This
experimental study was the first to show that only a
certain degree of reversion, but not complete reversal,
from an advanced stage of cirrhosis, is likely to be
possible. 
These seminal studies were relevant to start to
envisage a scenario in which the rise and fall of activated
HSC during liver injury (Fig. 5) is then modulated by a
balance of several anti-apoptotic and pro-apoptotic
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Fig. 5. The rise and fall of
activated, MF-like, hepatic
stellate cells as a balance
between anti-apoptotic (i.e.,
pro-survival) and pro-apoptotic
factors.
factors and signals coming from either the extracellular
or intracellular environment (Elsharkawy et al. 2005).
Moreover, apoptosis of HSC/MFs is of course followed
by a decrease in collagen production and synthesis of
tissue inhibitor of metalloproteases (TIMPs), two major
features that favor accumulation of ECM in CLDs, as
well as by an increase in activity of matrix
metalloproteinases able to degrade fibrillar collagen. 
These studies, showing that apoptosis of MFs is
followed by reversion of experimental fibrosis,
stimulated the search for drugs and therapeutic strategies
designed to selectively stimulate apoptosis of pro-
fibrogenic cells. 
Clinical evidence of liver fibrosis reversion
A number of clinical studies have reported evidence
suggesting that reversion or regression of fibrosis and
cirrhosis may also occur in human patients affected by
chronic viral infection (Shiratori et al., 2000; Kweon et
al., 2001; Poynard et al., 2002; Dienstag et al., 2003;
Farci et al., 2004; Serpaggi et al., 2006; Hui et al., 2007);
autoimmune hepatitis (Dufour et al., 1997), alcoholic
(Wakim-Fleming and Mullen, 2005) and non-alcoholic
(Dixon et al., 2004; Kral et al., 2004) steatohepatitis
following effective therapy and/or removal of aetiology.
Along these lines, the most extensively investigated
condition is represented by chronic HCV infection in
patients receiving a standard therapy based on
administration of IFN-α alone or in association with
ribavirin (Shiratori et al., 2000; Poynard et al., 2002;
Farci et al., 2004). Positive results in terms of fibrosis
regression have been described for those responder
patients in which viral clearance was obtained. 
However, as pointed out by different authors
(Desmet and Roskams, 2004; Henderson and Iredale,
2007; Ismail and Pinzani, 2009), no convincing or
incontrovertible evidence has been reported for complete
reversal of advanced cirrhosis. Indeed, when a careful
analysis of these studies is performed, one can only
prudently state that they describe a variable degree of
fibrosis reversion in human patients. On the other hand,
as shown also in animal models (Issa et al., 2004), in
true cirrhosis a complete reversion of deranged vascular
architecture is likely to be impossible. 
As discussed by Ismail and Pinzani (2009), this may
also be related to a substantial lack of a common
language and of a worldwide consensus on definitions
and terms, that is to be able to unequivocally distinguish
conditions of pre-cirrhosis from true cirrhosis, the
former being able to show some degree of reversal,
sometimes even significant, the latter being unable to do
so. Indeed, cirrhosis can appear in a very broad spectrum
of variants, sometimes defined as early, fully developed,
active and inactive, with a note of confusion added to the
scenario by the too many histopathological scoring
systems available. Moreover, as recently suggested, we
definitively need a system (and the related technical
tools) able to classify cirrhosis in different stages,
including a clearcut distinction between compensated
and de-compensated cirrhosis. The reader can refer for a
more detailed analysis and discussion of this crucial
point to the excellent recent review by Ismail and
Pinzani (Ismail and Pinzani, 2009). 
The issue of induction of MF apoptosis: relevant
concepts and emerging therapeutic strategies
As mentioned in the previous sections, HSC/MFs
and, likely, also MFs of different origin, can undergo
apoptosis when the injurious stimulus responsible for
chronic liver damage is withdrawn and remodeling of
ECM is required. Indeed, HSC apoptosis is known to
occur as a “normal” event after acute liver injury at the
end of the healing reaction and then as a rather
physiological and necessary “switch off” mechanism. 
However, as pointed out by different laboratories
(Elsharkawy et al., 2005; Novo et al., 2006b; Henderson
and Iredale, 2007) progressive fibrogenesis in chronic
liver injury, irrespective of aetiology, is characterized by
an apparent failure or forestall of MFs apoptosis. This
condition is believed to represent the consequence of
either an altered balance between factors favouring
survival and those favoring apoptosis (see Fig. 5)
(Elsharkawy et al., 2005; Henderson and Iredale, 
2007). 
According to this view, it has been shown, for
example, that apoptosis of HSC/MFs is significantly and
directly inhibited by TIMP1 (Murphy et al., 2002),
which is typically over-expressed in either experimental
and clinical conditions of CLDs (Henderson and Iredale,
2007). Moreover, synthetic MMP inhibitors were also
found in the same study to inhibit HSC apoptosis and
this was confirmed by analyses showing that persistent
expression of TIMP-1 mRNA during the course of
experimental cirrhosis was correlated with persistence of
activated HSC quantified by α-SMA staining, while in
fibrosis, loss of activated HSC correlated with a
reduction in TIMP-1 mRNA. The conclusion reached
was that TIMP-1 was able to inhibit apoptosis of
activated HSC via MMP inhibition. 
Another obvious element in this puzzle is
represented by the fact that several growth factors which
are over-produced in the chronically injured liver can of
course stimulate survival signals and pathways, with a
central role identified for nuclear factor κB (NF-κB)
activation deserving to be mentioned. Indeed, several
studies have outlined that NF-κB activation, a well
known event in activated HSC/MFs that may be related
to the action of several growth factors and/or ROS
(Bataller and Brenner, 2005; Elsharkawy et al., 2005;
Friedman 2008a,b), is crucial for the survival of either
rodent or human MFs (Oakley et al., 2005, 2009; Watson
et al., 2008). This is the case, for example, for the
recently identified “survival” role of angiotensin II
which acts by activating IÎB kinase, leading to
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phosphorylation of RelA at Ser536 (Oakley et al., 2009). 
Where the equilibrium between survival and pro-
apoptotic signals is concerned, another recent report has
finally established a critical dual role of mature nerve
growth factor (NGF) and of its pro-peptide (proNGF),
acting as pro-apoptotic and survival signals, respectively.
In the latter study (Kendall et al., 2009) authors were
able to show that during resolution of fibrosis the
cleavage of proNGF by MMP-7 altered the proNGF/
mature NGF balance facilitating apoptosis of MFs (that
co-express both p75 neurotrophin receptor and sortilin,
the receptors for the two peptides). 
The overall scenario has been implemented by a
study in which activation of human HSC has also been
reported to result in an anti-apoptotic gene
reprogramming, leading human HSC/MFs to over-
express Bcl-2 and to survive to pro-apoptotic stimuli
found to be effective on rat HSC/MFs, including FasL,
TNF and excess oxidative stress (Novo et al., 2006b).
Immunohistochemical data provided in the same study
clearly indicate that myofibroblast-like cells at the
interface between septa and parenchyma significantly
overexpress Bcl-2, confirming the possible in vivo
relevance of in vitro data. Interestingly, this “survival”
attitude related to Bcl2 overexpression, a finding also
confirmed in another study (Watson et al., 2008), was
lost during senescence of human HSC/MFs that became
susceptibile to apoptosis induction. Indeed, a recent
report has confirmed and elegantly further addressed the
relevance of senescence for the balance between
HSC/MFs survival and apoptosis (Krizhanovsky et al.,
2008), These authors first detected the accumulation of
senescent HSC-derived cells in murine fibrotic livers
and then, by elegant experiments in which mice lacking
key senescence regulators were used, were able to show
that HSC/MFs continued to proliferate, leading to
excessive fibrosis, then suggesting that senescence may
represent a “natural” way to eliminate MFs. Indeed,
senescent HSC were characterized by a gene expression
profile consistent not only with cell cycle exit, but also
with decreased synthesis of ECM components, increased
release of ECM remodeling enzymes and enhanced
immune surveillance. Of relevance, senescent HSC were
found to release cytokines or receptors that are known to
potentiate natural killer (NK) cell function, and indeed
NK cells were found in close proximity to senescent
cells in murine fibrotic livers and senescent cells were
selectively targeted by NK cells, either in culture or in
vivo, a scenario that becomes predominant under
conditions compatible with fibrosis resolution (i.e., after
cessation of administration of CCl4) and is likely to
contribute to eliminate activated HSC also 
under conditions of recovery from an acute liver 
injury. 
The overall scenario just described, as has
progressively emerged in the last decade, has stimulated
the search for therapeutic strategies designed to
selectively target HSC/MFs and, probably, to induce
their apoptosis. Several drugs and agents have been
tested and shown to be able to limit (to a variable extent)
fibrosis in animal models, and the interested reader can
refer to an excellent dedicated review by the group of
Derek Mann (Muddu et al., 2007 and references therein).
Within this list of drugs, several have been specifically
found to induce MFs apoptosis, including the NF-κB
inhibitor sulfasalazine, the mycotoxin gliotoxin, the
proteasome inhibitor bortezomib, the agent curcumurin,
as well as NGF or a soluble TGFß receptor. Other
therapeutic options have been tested by attempting to
enhance MMP activity, for example by employing
antibodies against TIMPs, or by inhibiting HSC
activation by treatment with hepatocyte growth factor
(HGF). 
Of relevance, a recent report (Oakley et al., 2009), in
describing the pro-survival action of AT-II, has also
provided convincing evidence for the potential
antifibrotic efficacy of administration of captopril, an
inhibitor of angiotensin-converting enzyme, as well as
the necessary base of knowledge to understand why
drugs able to affect the renin - angiotensin system have
been shown to inhibit fibrosis in animal models (Bataller
et al., 2007). Most important, this also explains the
reported positive effects of candesartan, a drug designed
to specifically block angiotensin receptor 1 (AT1), on
both hepatic venous pressure and decreased serum levels
of markers of fibrosis in compensated cirrhotic patients
(Debernardi-Venon et al., 2007). The latter study is
relevant, as recently discussed (Pinzani, 2009), because
positive effects of candesartan have been obtained at a
dosage not affecting mean arterial pressure in these
patients. 
Conclusions 
Liver fibrogenesis is a dynamic and highly
integrated molecular, tissue and cellular process that
leads to the progressive accumulation of extracellular
matrix (ECM) components in an attempt to limit hepatic
damage in a CLD irrespective of the aetiology.
Progressive fibrogenesis, sustained by a heterogeneous
population of MFs that may originate from different
cells sources, has a tremendous clinical impact because
it can lead to the end-point of cirrhosis and related
complications, including the development of
hepatocellular carcinoma. Basic and clinical studies, by
continuously unravelling molecular mechanisms
involved in pro-fibrogenic phenotypic responses of MFs,
including those involved in the critical survival/
apoptosis equilibrium, are currently offering new
“targets” for future anti-fibrotic strategies to test with
properly designed clinical trials that may represent
effective alternative options for a changing scenario in
which fibrosis (but not advanced cirrhosis) can be
reverted and liver transplantation (i.e., at present the
only effective therapy for end-stage disease) possibly at
least delayed. 
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